FY2024 Earnings Forecast for bluebird bio, Inc. (NASDAQ:BLUE) Issued By Cantor Fitzgerald

bluebird bio, Inc. (NASDAQ:BLUE) – Equities research analysts at Cantor Fitzgerald lifted their FY2024 earnings per share (EPS) estimates for shares of bluebird bio in a report issued on Monday, September 16th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the biotechnology company will post earnings of ($1.31) per share for the year, up from their previous estimate of ($1.78). Cantor Fitzgerald has a “Neutral” rating on the stock. The consensus estimate for bluebird bio’s current full-year earnings is ($1.66) per share.

BLUE has been the subject of several other research reports. Royal Bank of Canada restated a “sector perform” rating and set a $4.00 target price on shares of bluebird bio in a research note on Thursday, August 15th. Bank of America decreased their target price on shares of bluebird bio from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, August 15th. Barclays decreased their price target on bluebird bio from $8.00 to $4.00 and set an “overweight” rating on the stock in a research note on Thursday, August 15th. Robert W. Baird decreased their price objective on shares of bluebird bio from $7.00 to $6.00 and set an “outperform” rating on the stock in a research note on Thursday, August 15th. Finally, JPMorgan Chase & Co. cut bluebird bio from an “overweight” rating to a “neutral” rating in a report on Thursday, August 15th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat, bluebird bio presently has a consensus rating of “Hold” and a consensus price target of $4.74.

bluebird bio Stock Performance

NASDAQ:BLUE opened at $0.49 on Wednesday. bluebird bio has a 1 year low of $0.48 and a 1 year high of $5.53. The firm’s fifty day simple moving average is $0.85 and its 200 day simple moving average is $1.00. The firm has a market capitalization of $53.79 million, a PE ratio of -0.66 and a beta of 0.75.

Institutional Investors Weigh In On bluebird bio

A number of institutional investors and hedge funds have recently modified their holdings of the business. Masters Capital Management LLC bought a new stake in shares of bluebird bio in the 4th quarter valued at about $1,380,000. Mirae Asset Global Investments Co. Ltd. grew its stake in bluebird bio by 38.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 325,111 shares of the biotechnology company’s stock valued at $416,000 after acquiring an additional 90,139 shares during the period. Virtu Financial LLC acquired a new position in shares of bluebird bio in the 4th quarter valued at approximately $317,000. HBK Investments L P acquired a new position in shares of bluebird bio in the fourth quarter valued at approximately $2,070,000. Finally, Vestal Point Capital LP bought a new position in bluebird bio during the 4th quarter worth about $2,967,000. 87.43% of the stock is owned by institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.